Navigation Links
Study identifies new approach to improving treatment for MS and other conditions
Date:5/17/2013

(SACRAMENTO, Calif.) Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS.

The findings of the research study, published online today in the journal EMBO Molecular Medicine could have therapeutic applications for MS as well as cerebral palsy and leukodystrophies, all disorders associated with loss of white matter, which is the brain tissue that carries information between nerve cells in the brain and the spinal cord.

The target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord. The mitrochronical TSPO is located on the outer surface of mitochondria, cellular structures that supply energy to the cells. Damage to the fatty coating, or myelin, slows the transmission of the nerve signals that enable body movement as well as sensory and cognitive functioning.

The scientists identified mitochondrial TSPO as a potential therapeutic target when mice that had symptoms of MS improved after being treated with the anti-anxiety drug etifoxine, which interacts with mitochondrial TSPO. When etifoxine, a drug clinically available in Europe, was administered to the MS mice before they had clinical signs of disease, the severity of the disease was reduced when compared to the untreated lab animals. When treated at the peak of disease severity, the animals' MS symptoms improved.

"Etifoxine has a novel protective effect against the loss of the sheath that insulates the nerve fibers that transmit the signals from brain cells," said Wenbin Deng, principal investigator of the study and associate professor of biochemistry and molecular medicine at UC Davis.

"Our discovery of etifoxine's effects on an MS animal model suggests that mitochondrial TSPO represents a potential therapeutic target for MS drug development," said Deng.

"Drugs designed to more precisely bind to mitochondrial TSPO may help repair the myelin sheath of MS patients and thereby even help restore the transmission of signals in the central nervous system that enable normal motor, sensory and cognitive functions," he said.

Deng added that better treatments for MS and other demyelinating diseases are needed, especially since current FDA-approved therapies do not repair the damage of immune attacks on the myelin sheath.

The UC Davis research team hopes to further investigate the therapeutic applications of mitochondrial TSPO in drug development for MS and other autoimmune diseases. To identify more efficacious and safer drug candidates, they plan to pursue research grants that will enable them to test a variety of pharmacological compounds that bind to mitochondrial TSPO and other molecular targets in experimental models of MS and other myelin diseases.

The journal paper is entitled, "A TSPO ligand is protective in a mouse model of multiple sclerosis."


'/>"/>

Contact: Charles Casey
charles.casey@ucdmc.ucdavis.edu
916-734-9048
University of California - Davis Health System
Source:Eurekalert

Related medicine news :

1. Study: Peer-referral programs can increase HIV-testing in emergency departments
2. New study pinpoints biochemical mechanism underlying fibrosis following glaucoma surgery
3. Study: Patient openness to research can depend on race and sex of study personnel
4. The Institute of Regenerative & Molecular Orthopedics Applauds Newly Released Study on Platelet-Rich Plasma
5. Study suggests new role for ECMO in treating patients with cardiac arrest and profound shock
6. Bel Marra Health Reports on a New Study Revealing a Natural Remedy for Hypertension, Insomnia, and Aging
7. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
8. New Study Reveals that Fitness Levels May Affect Attention Span, Making Weight Loss, Such as With Prescopodene, Helpful With Promoting Concentration
9. New study recommends using active videogaming (exergaming) to improve childrens health
10. Study: Brain makes call on which ear is used for cell phone
11. 2013 Is the Year of Mobility in Government: Study Shows Media Landscape Shifting in Government Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from Pixel Film ... Final Cut Pro X. Each user can select from up to 40 effect overlays. ... blur, focus offset, hue, saturation, value, contrast, glow, and more all within a click ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, Inc. presented ... a VeinViewer® Vision vein finder for the nursing school simulation lab. ... and draw blood, combining technology with traditional technique. , “VeinViewer is a wonderful ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... Opelousas, LA (PRWEB) , ... February 12, 2016 , ... ... of St. Landry and Evangeline Parishes. The purpose of these scholarships is to ... to encourage those individuals to seek employment within these two parishes. , “We ...
(Date:2/12/2016)... ... 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — ... Churchill said, “Those who don’t learn from history are doomed to repeat it.” , An ... knocking this year. But that takes time. , Take a close look at the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
(Date:2/11/2016)... 2016   Health 2.0 , the premiere showcase ... announced today " 10 Year Global Retrospective ", a ... the past ten years.   --> ... 2.0 has served as the preeminent thought-leader in the ... of technologies, companies, innovators, and patient-activists through an array ...
Breaking Medicine Technology: